MedTrace Logo

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

NCT03087591 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-10-10

Study results available
· View outcomes & findings →

Summary

This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back. APN401 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Metastatic Malignant Neoplasm in the Brain
  • Metastatic Solid Neoplasm
  • Recurrent Colorectal Carcinoma
  • Recurrent Pancreatic Carcinoma
  • Recurrent Solid Neoplasm
  • Stage IV Colorectal Cancer
  • Stage IV Pancreatic Cancer
  • Stage IVA Colorectal Cancer
  • Stage IVA Pancreatic Cancer
  • Stage IVB Colorectal Cancer
  • Stage IVB Pancreatic Cancer
  • Unresectable Solid Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Pierre Triozzi · Wake Forest University Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-28
Primary Completion
2019-07-31
Completion
2020-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03087591 on ClinicalTrials.gov